Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OpACIN: Neoadjuvant vs Adjuvant Ipilimumab + Nivolumab in Stage III Melanoma
NCT02437279Phase 1Unknown
- Sponsor
- Netherlands Cancer Institute
- Start
- Nov 2016
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ipilimumab and nivolumab in cutaneous melanoma (CM) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Alteration in magnitude of neo-antigen specific T cell response at 12 weeks, Safety as measured by SUSARs at 12 weeks and 2 more. Status: unknown.
02
Drugs
ipilimumabnivolumab
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02437279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02437279.